WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock Ownership - Who owns Esperion Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Esperion Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Benjamin HalladayChief Financial Officer2026-03-176,424$2.71
$17.38kSell
Benjamin LookerChief Legal Officer2026-03-175,708$2.70
$15.43kSell
Sheldon L. KoenigPresident and CEO2026-03-1725,578$2.72
$69.55kSell
Benjamin LookerGeneral Counsel2026-01-201,689$2.88
$4.87kSell
Sheldon L. KoenigPresident and CEO2025-12-1748,244$3.67
$177.20kSell
Benjamin LookerGeneral Counsel2025-12-176,517$3.67
$23.90kSell
Benjamin HalladayChief Financial Officer2025-12-177,337$3.67
$26.90kSell
Benjamin LookerGeneral Counsel2025-10-171,248$2.62
$3.27kSell
Sheldon L. KoenigPresident and CEO2025-09-1728,427$2.79
$79.25kSell
Benjamin HalladayChief Financial Officer2025-09-177,046$2.81
$19.79kSell

1 of 2

ESPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ESPR insiders and whales buy or sell their stock.

ESPR Shareholders

What type of owners hold Esperion Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc6.89%17,682,201$44.29MInstitution
Vanguard Group Inc5.82%14,945,454$37.44MInstitution
Two Seas Capital LP4.63%11,902,521$29.82MInstitution
Wasatch Advisors LP3.68%9,445,759$23.66MInstitution
D E Shaw Co Inc2.69%6,903,483$17.29MInstitution
Orbimed Advisors LLC2.32%5,965,498$14.94MInstitution
State Street Corp2.31%5,930,296$14.86MInstitution
Geode Capital Management LLC2.23%5,737,651$14.37MInstitution
Marshall Wace LLP2.13%5,471,611$13.71MInstitution
Two Sigma Investments LP1.85%4,742,082$11.88MInstitution

1 of 3

ESPR vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ESPR58.90%16.57%Net SellingNet Selling
BIOA65.62%27.59%Net SellingNet Selling
ETON58.24%32.85%Net SellingNet Buying
TLRY9.64%17.71%Net BuyingNet Buying
IRWD72.40%27.60%Net SellingNet Selling
View Top Pharmaceutical Stocks

Esperion Therapeutics Stock Ownership FAQ

Who owns Esperion Therapeutics?

Esperion Therapeutics (NASDAQ: ESPR) is owned by 58.90% institutional shareholders, 16.57% Esperion Therapeutics insiders, and 24.53% retail investors. Target N. V. Biotech is the largest individual Esperion Therapeutics shareholder, owning 4.48M shares representing 1.74% of the company. Target N. V. Biotech's Esperion Therapeutics shares are currently valued at $11.64M.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.